Clinical Trial: Safety, Tolerability and Pharmacokinetics of RNV-166 in Healthy Male Volunteers

U.S., Sept. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07809360) titled 'Safety, Tolerability and Pharmacokinetics of RNV-166 in Healthy Male Volunteers' on Feb. 10.

Brief Summary: This Phase 1 first-in-human clinical study evaluated the safety, tolerability, and pharmacokinetics of RNV-166 following single ascending dose (SAD) and multiple ascending dose (MAD) administration in healthy participants. Single oral doses of RNV-166 ranging from 200 mg to 1600 mg were assessed, including evaluation under fed (high-fat meal) conditions to characterize food effects on pharmacokinetics. Multiple ascending doses were administered once daily for up to 28 days to assess safety, tolerability, and pharmacokinetic p...